A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
DR REDDYS LABORATORIES LTD
RDY
$10.0B
Mkt Cap
$11.79
-0.08%
DR REDDYS LABORATORIES LTD (RDY) has a 5-year average return on invested capital (ROIC) of 13.7%. This indicates solid capital allocation.
DR REDDYS LABORATORIES LTD (RDY) has a market capitalization of $10.0B. It is classified as a large-cap stock.
Yes, DR REDDYS LABORATORIES LTD (RDY) pays a dividend with a trailing twelve-month yield of 66.53%. The company also returns capital through share buybacks, with a buyback yield of 13.87%.
DR REDDYS LABORATORIES LTD (RDY) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
DR REDDYS LABORATORIES LTD (RDY) reported annual revenue of $325.5 billion in its most recent fiscal year, based on SEC EDGAR filings.
DR REDDYS LABORATORIES LTD (RDY) has a net profit margin of 0.2%. This is a modest margin.
DR REDDYS LABORATORIES LTD (RDY) generated $223 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
TEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS Not applicable.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 325.5B | 325.5B | 279.2B | 245.9B | 214.4B | 189.7B |
| Net Income | 671M | 671M | 668M | 548M | 311M | 236M |
| EPS | $0.79 | $0.79 | $0.80 | $0.66 | $0.37 | $0.30 |
| Free Cash Flow | 223M | 223M | 348M | 578M | 177M | 355M |
| ROIC | 14.2% | 14.2% | 17.9% | 17.9% | 10.3% | 8.4% |
| Gross Margin | 0.7% | 0.7% | 0.7% | 0.7% | 0.7% | 0.7% |
| Debt/Equity | 0.14 | 0.14 | 0.07 | 0.06 | 0.18 | 0.17 |
| Dividends/Share | $7.84 | $7.84 | $7.98 | $6.00 | $4.99 | $5.34 |
| Operating Income | 842M | 842M | 813M | 695M | 389M | 332M |
| Operating Margin | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.2% |
| ROE | 17.0% | 18.4% | 21.6% | 20.6% | 12.8% | 10.7% |
| Shares Outstanding | 849M | 849M | 833M | 830M | 832M | 776M |
| Metric | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 154.7B | 140.8B | 142.0B | 153.9B | 174.6B | 189.7B | 214.4B | 245.9B | 279.2B | 325.5B | 325.5B |
| Gross Margin | 59.6% | 55.6% | 0.8% | 0.8% | 0.7% | 0.7% | 0.7% | 0.7% | 0.7% | 0.7% | 0.7% |
| R&D | 17.8B | 19.6B | 281M | 226M | 204M | 226M | 230M | 236M | 274M | 320M | 320M |
| SG&A | 45.7B | 46.4B | 720M | 707M | 665M | 747M | 818M | 828M | 926M | 1.1B | 1.1B |
| EBIT | 29.6B | 13.5B | 183M | 302M | 212M | 332M | 389M | 695M | 813M | 842M | 842M |
| Op. Margin | 19.1% | 9.6% | 0.1% | 0.2% | 0.1% | 0.2% | 0.2% | 0.3% | 0.3% | 0.3% | 0.3% |
| Net Income | 20.0B | 12.0B | 151M | 272M | 259M | 236M | 311M | 548M | 668M | 671M | 671M |
| Net Margin | 12.9% | 8.5% | 0.1% | 0.2% | 0.1% | 0.1% | 0.1% | 0.2% | 0.2% | 0.2% | 0.2% |
| Non-Recurring | 2.7B | 3.1B | 45M | 58M | 3.7B | 2.5B | 4.6B | 59M | 43M | 61M | 61M |
| Returns on Capital | |||||||||||
| ROIC | N/A | 7.6% | 0.1% | 9.9% | 9.9% | 8.4% | 10.3% | 17.9% | 17.9% | 14.2% | 14.2% |
| ROE | N/A | 9.5% | 0.2% | 13.7% | 12.7% | 10.7% | 12.8% | 20.6% | 21.6% | 18.4% | 17.0% |
| ROA | N/A | 10.9% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Cash Flow | |||||||||||
| Op. Cash Flow | 41.2B | 21.5B | 277M | 415M | 396M | 488M | 370M | 716M | 545M | 545M | 545M |
| Free Cash Flow | 29.2B | 9.2B | 134M | 314M | 332M | 355M | 177M | 578M | 348M | 223M | 223M |
| Owner Earnings | 31.0B | 10.2B | -11.4B | 239M | 231M | 313M | 214M | 562M | 367M | 345M | 345M |
| CapEx | 12.0B | 12.3B | 143M | 101M | 64M | 133M | 193M | 138M | 197M | 322M | 322M |
| Maint. CapEx | 10.3B | 11.3B | 11.7B | 176M | 165M | 175M | 156M | 154M | 178M | 200M | 200M |
| Growth CapEx | 1.8B | 1.0B | 0 | 0 | 0 | 0 | 37M | 0 | 19M | 122M | 122M |
| D&A | 10.3B | 11.3B | 11.7B | 176M | 165M | 175M | 156M | 154M | 178M | 200M | 200M |
| CapEx/OCF | 29.1% | 57.1% | 0.8% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 59.1% |
| Capital Allocation | |||||||||||
| Dividends Paid | 4.1B | 3.4B | 4.0B | 4.0B | 3.9B | 4.1B | 4.1B | 5.0B | 6.6B | 6.7B | 6.7B |
| Dividend Yield | 48.2% | 48.1% | 70.2% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 66.5% |
| Share Buybacks | 0 | 0 | 0 | 8.0M | 0 | 0 | 0 | 0 | 0 | 1.4B | 1.4B |
| Buyback Yield | N/A | N/A | N/A | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 13.9% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 65.7B | 58.0B | 48.5B | 41.4B | 48.0B | 68.6B | 13.9B | 56.2B | 56.2B |
| Balance Sheet | |||||||||||
| Net Debt | N/A | 45.2B | 736M | 523M | 265M | 211M | 250M | 94M | 156M | 486M | 486M |
| Cash & Equiv. | 4.9B | 3.9B | 41M | 32M | 27M | 203M | 196M | 70M | 85M | 61M | 61M |
| Long-Term Debt | N/A | 5.4B | 385M | 318M | 17M | 86M | 76M | 16M | 72M | 92M | 92M |
| Debt/Equity | N/A | 0.40 | 0.40 | 0.27 | 0.14 | 0.17 | 0.18 | 0.06 | 0.07 | 0.14 | 0.14 |
| Interest Coverage | 35.9 | 21.3 | 0.2 | 0.3 | 0.2 | 0.3 | 0.4 | 0.5 | 0.5 | 0.3 | 0.3 |
| Equity | N/A | 124.0B | 1.9B | 2.0B | 2.1B | 2.4B | 2.5B | 2.8B | 3.4B | 3.9B | 3.9B |
| Total Assets | N/A | 219.8B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Total Liabilities | N/A | 95.8B | 1.5B | 1.2B | 1.0B | 1.3B | 1.3B | 1.1B | 1.3B | 1.8B | 1.8B |
| Intangibles | 309M | 58M | 58M | 794K | 716K | 839K | 736K | 630K | 609K | 1.6M | 1.6M |
| Retained Earnings | N/A | 108.1B | 1.7B | 1.9B | 1.9B | 2.1B | 2.3B | 2.6B | 3.2B | 3.7B | 3.7B |
| Working Capital | N/A | 15.4B | 614M | 793M | 763M | 887M | 1.2B | 1.5B | 1.8B | 1.4B | 1.4B |
| Current Assets | N/A | 100.4B | 1.7B | 1.7B | 1.7B | 2.0B | 2.4B | 2.5B | 3.0B | 2.9B | 2.9B |
| Current Liabilities | N/A | 85.0B | 1.1B | 863M | 966M | 1.1B | 1.2B | 1.0B | 1.2B | 1.5B | 1.5B |
| Per Share Data | |||||||||||
| EPS | 23.40 | 14.42 | 0.18 | 0.33 | 0.31 | 0.30 | 0.37 | 0.66 | 0.80 | 0.79 | 0.79 |
| Owner EPS | 36.24 | 12.26 | -13.78 | 0.29 | 0.28 | 0.40 | 0.26 | 0.68 | 0.44 | 0.41 | 0.41 |
| Book Value | N/A | 148.56 | 2.34 | 2.44 | 2.48 | 3.05 | 3.02 | 3.38 | 4.04 | 4.65 | 4.65 |
| Cash Flow/Share | 48.22 | 25.76 | 0.33 | 0.50 | 0.48 | 0.63 | 0.44 | 0.86 | 0.65 | 0.64 | 1.03 |
| Dividends/Share | 4.80 | 4.06 | 4.81 | 4.83 | 4.72 | 5.34 | 4.99 | 6.00 | 7.98 | 7.84 | 7.84 |
| Shares Out. | 855.4M | 835.0M | 829.7M | 829.3M | 830.1M | 776.3M | 831.6M | 830.3M | 832.9M | 849.4M | 849.4M |
| Valuation | |||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 14.9 |
| P/FCF | 0.2 | 0.7 | 37.7 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 44.9 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 12.5 |
| Price/Book | N/A | 3.2 | 178.0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 2.5 |
| Price/Sales | 3.6 | 3.2 | 2.7 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0 |
| FCF Yield | 428.5% | 150.5% | 2.7% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 2.2% |
| Market Cap | 6.8B | 6.1B | 5.1B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.0B |
| Avg. Price | 9.96 | 8.45 | 6.86 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.79 |
| Year-End Price | 8.22 | 7.40 | 6.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.79 |
DR REDDYS LABORATORIES LTD passes 4 of 9 quality checks, suggesting mixed fundamentals.
On a free-cash-flow basis, the stock trades at 37.4x vs a median of 0.7x. The company's 5-year average ROIC is 13.7% with a gross margin of 0.7%. Total shareholder yield (dividends + buybacks) is 80.4%.
DR REDDYS LABORATORIES LTD (RDY) has a debt-to-equity ratio of 0.14. This indicates a conservatively financed balance sheet.
DR REDDYS LABORATORIES LTD (RDY) reported earnings per share (EPS) of $0.79 in its most recent fiscal year.
DR REDDYS LABORATORIES LTD (RDY) has a return on equity (ROE) of 18.4%. This indicates the company generates strong returns for shareholders.
DR REDDYS LABORATORIES LTD (RDY) has a 5-year average gross margin of 0.7%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 10 years of financial data for DR REDDYS LABORATORIES LTD (RDY), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
DR REDDYS LABORATORIES LTD (RDY) has a book value per share of $4.65, based on its most recent annual SEC filing.
No recent press releases.